U.S. Healthcare Services Stock News

NasdaqGS:LFCR
NasdaqGS:LFCRLife Sciences

Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...
NasdaqGS:TRS
NasdaqGS:TRSPackaging

Assessing TriMas (TRS) Valuation After Recent Share Price Momentum And Undervaluation Narrative

Why TriMas is on investors’ radar today TriMas (TRS) has drawn fresh interest as investors look at its recent share performance alongside its value score of 3 and current market capitalization of about US$1.32b. The stock shows a 1 day return of 1.23%, a month return decline of 2.21%, and a past 3 months return of 3.77%, while the 1 year total return stands at 42.54%. See our latest analysis for TriMas. The recent 1 day share price gain of 1.23% to US$35.47 comes after a weaker 7 day and year...
NYSE:LTC
NYSE:LTCHealth Care REITs

Is LTC Properties (LTC) Offering Value After Strong Multi Year Share Price Gains

If you are wondering whether LTC Properties at around US$38.99 is offering good value today, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock has delivered a 0.6% return over the last week, a 1.0% decline over the past month, and is up 12.5% year to date and 15.5% over the past year, with longer term returns of 41.0% over three years and 26.1% over five years. Recent attention on LTC Properties has focused on its position...
NYSE:ED
NYSE:EDIntegrated Utilities

Does New US$3.5 Billion Credit Line And EPS Targets Change The Bull Case For Consolidated Edison (ED)?

Consolidated Edison recently entered into a new US$3.50 billions revolving credit facility to support its commercial paper programs and general corporate purposes, shortly after reporting Q4 2025 revenue and adjusted EPS that topped Wall Street expectations. Together with management’s plans for a five-year adjusted EPS compound annual growth rate of 6% to 7%, the expanded credit access highlights how the utility is prioritizing both liquidity and earnings visibility. We’ll now look at how...
NYSE:BEKE
NYSE:BEKEReal Estate

KE Holdings (NYSE:BEKE) Margin Compression Tests Premium P/E And Bullish Growth Narrative

KE Holdings (NYSE:BEKE) FY 2025 Results Overview KE Holdings (NYSE:BEKE) has wrapped up FY 2025 with fourth quarter revenue of C¥22.2b and basic EPS of C¥0.08, alongside trailing 12 month revenue of C¥94.6b and basic EPS of C¥2.70 that frame the latest print for investors watching the stock around C¥16.90 per share. The company has seen quarterly revenue range from C¥22.1b to C¥26.0b over the past year, with basic EPS moving between C¥0.08 and C¥1.16 across FY 2025. This gives a clearer view...
NYSE:ABBV
NYSE:ABBVBiotechs

What AbbVie (ABBV)'s Early ABBV-295 Obesity Data Means For Shareholders

Earlier this month, AbbVie reported positive Phase 1 multiple-ascending-dose results for its investigational obesity drug ABBV-295, a long-acting amylin analog that induced clinically meaningful, dose-dependent weight loss with generally mild gastrointestinal side effects over 12–13 weeks of treatment. The data highlight AbbVie’s push into a mechanistically distinct class of obesity therapies beyond incretin-based drugs, adding another potential pillar to its already broad pipeline in...
NYSE:ZEPP
NYSE:ZEPPElectronic

Zepp Health (ZEPP) Q4 Loss Narrows To US$0.69 EPS Challenging Bearish Profitability Narratives

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...
OTCPK:DIDI.Y
OTCPK:DIDI.YTransportation

A Look At DiDi Global (OTCPK:DIDI.Y) Valuation After Revenue Growth And Softer Profitability

Why DiDi Global’s latest earnings matter for shareholders DiDi Global (OTCPK:DIDI.Y) has released fourth quarter and full year 2025 results, with higher reported sales alongside a quarterly net loss and lower annual net income, giving you a mixed profitability picture to weigh. For the fourth quarter, DiDi Global reported sales of CNY 58,445 million compared with CNY 52,914 million a year earlier, and a net loss of CNY 338 million versus a CNY 1,341 million loss in the prior year...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Ross Stores Expansion Tests Off Price Model And Community Focus In 2026

Ross Stores (NasdaqGS:ROST) is opening 17 new locations across 11 U.S. states as part of its 2026 expansion plan. The openings mark the first phase of a targeted 110 new stores the company aims to add this fiscal year. Each grand opening includes charitable contributions to local youth organizations in the surrounding communities. Ross Stores operates off price retail banners that focus on discounted apparel and home goods, a segment that often attracts value oriented shoppers. The decision...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed

Earlier in February 2026, ACADIA Pharmaceuticals received a formal negative opinion from the EMA’s CHMP on its marketing application for trofinetide in Rett syndrome, while also appointing biopharma finance executive Jonathan M. Poole to its Board and preparing a leadership presentation at the Longwood Healthcare Leaders Miami conference. This mix of regulatory setback in Europe and added financial expertise on the Board highlights a pivotal moment for ACADIA’s rare disease and CNS growth...
NasdaqGS:VNET
NasdaqGS:VNETIT

VNET Group (NasdaqGS:VNET) EPS Loss Deepens In Q3 2025 Challenging Profitability Narratives

VNET Group (NasdaqGS:VNET) just reported FY 2025 third quarter revenue of C¥2.6b with a basic EPS loss of C¥1.14, while trailing twelve month revenue stood at C¥9.5b alongside a basic EPS loss of C¥2.17. The company has seen quarterly revenue move from C¥2.0b in Q2 2024 to C¥2.1b in Q3 2024, C¥2.2b in Q4 2024 and Q1 2025, C¥2.4b in Q2 2025 and now C¥2.6b in Q3 2025, with EPS swinging between a profit of C¥1.19 in Q3 2024 and losses including C¥0.89 in Q1 2025 and C¥1.14 in the latest quarter...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

SAIC (SAIC) Earnings Growth And 5% Margin Reinforce Bullish Profitability Narratives

Science Applications International (SAIC) has just posted fresh FY 2026 numbers, with third quarter revenue of US$1,866 million and basic EPS of US$1.70, alongside trailing 12 month revenue of US$7.4 billion and EPS of US$7.86. Over recent quarters the company has seen revenue range from US$1,769 million to US$1,877 million and quarterly EPS move between US$1.43 and US$2.72. This gives investors a clearer view of how the current run rate feeds into those trailing figures. With trailing net...
NYSE:AES
NYSE:AESRenewable Energy

Is AES (AES) Now Offering Value After Recent Share Price Weakness?

If you are wondering whether AES at around US$14.20 is now priced attractively or still has room to fall further, this article breaks down what the current share price implies about value. The stock has had a mixed run, with a 0.1% move over the last 7 days, a 12.8% decline over the past month, a 4.2% decline year to date, a 15.0% gain over the past year, and deeper 3 year and 5 year declines of 28.1% and 33.9% respectively. These moves sit against a backdrop of ongoing attention on...
NasdaqGS:URBN
NasdaqGS:URBNSpecialty Retail

Vans 60th Anniversary On Rotation Rollout Might Change The Case For Investing In Urban Outfitters (URBN)

In March 2026, Vans announced the latest installment of Urban Outfitters’ On Rotation experiential retail platform, bringing Vans’ 60th Anniversary Off The Wall campaign to life in Urban Outfitters stores and online with a curated mix of sneakers, apparel, and accessories across key U.S. locations. This collaboration not only extends Urban Outfitters’ earlier On Rotation installations with Nike and UGG but also adds live talent and immersive in-store elements, underscoring the retailer’s...
NasdaqGS:CSWC
NasdaqGS:CSWCCapital Markets

Is Capital Southwest (CSWC) Pricing Look Stretched After Recent Pullback From One Year Highs?

Wondering if Capital Southwest at around US$21.38 is offering fair value or a possible mispricing? This article walks through the key numbers so you can judge for yourself. The stock has seen a 3.1% decline over the past 7 days and 6.3% over the last 30 days, despite a 10.2% return over 1 year and 76.8% over 3 years. Recent coverage has focused on Capital Southwest's role as a business development company and how its market position and portfolio decisions feed into investor expectations...
NasdaqGS:REAL
NasdaqGS:REALSpecialty Retail

Can RealReal (REAL) Turn Leadership Changes And Designer Partnerships Into Lasting Brand Advantage?

The RealReal recently expanded its leadership and governance team, adding Fanatics Commerce COO Jennifer McKeehan to its board while appointing Tiffany Stevenson as Chief People Officer and Tom Hanrahan as Chief Revenue Officer, and also saw Niki Leondakis step down from the board as of March 6, 2026. At the same time, luxury designer Alejandra Alonso Rojas chose The RealReal as a partner to extend the life of her certified sustainable garments, underscoring the platform’s role in...
NasdaqGS:DLTR
NasdaqGS:DLTRConsumer Retailing

Dollar Tree (DLTR) Margin Compression To 5.9% Tests Bullish Earnings Narratives

Dollar Tree (DLTR) has just posted its latest FY 2026 numbers, with Q3 revenue of US$4.8b and basic EPS of US$1.20 setting the tone for the year to date. The company has seen quarterly revenue move from US$4.1b in Q2 FY 2025 to US$4.6b in Q1 FY 2026 and US$4.8b in Q3 FY 2026, while basic EPS has ranged from US$0.66 to US$1.47 over the same stretch, giving you a clear read on how sales and earnings are tracking into the back half of the year. With trailing 12 month net income described as high...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Why Stoke Therapeutics (STOK) Is Down 11.4% After NEJM Data on Dravet Syndrome Drug - And What's Next

In March 2026, Stoke Therapeutics and Biogen reported New England Journal of Medicine data showing that investigational antisense therapy zorevunersen produced substantial, durable seizure reductions and multi-year cognitive and behavioral improvements in children and adolescents with Dravet syndrome on top of standard anti-seizure medicines, with an overall safety profile the companies describe as generally well tolerated. The publication is important because it presents multi-year...
NYSE:NEU
NYSE:NEUChemicals

How Structural Oversupply In Petroleum Additives At NewMarket (NEU) Has Changed Its Investment Story

Recently, NewMarket Corporation has come under pressure as its core petroleum additives business faces structural oversupply, with global capacity additions outstripping demand and intensifying competition from Chinese exporters. An additional concern for investors is that bearish research has highlighted how NewMarket’s heavy reliance on this challenged segment could weigh on overall profitability despite past diversification efforts. Against this backdrop, we’ll explore how persistent...
NasdaqGS:VFS
NasdaqGS:VFSAuto

VinFast Auto (NasdaqGS:VFS) Loss Deepens In Q3 EPS And Reinforces Bearish Profitability Concerns

VinFast Auto (NasdaqGS:VFS) has just posted another loss making quarter, with Q3 FY 2025 revenue of about ₫18.1 trillion and basic EPS of a loss of ₫10,238.74, set against a trailing twelve month revenue base of roughly ₫67.5 trillion and a cumulative loss of about ₫92.5 trillion. Over recent periods the company has seen quarterly revenue move from about ₫8.7 trillion in Q2 FY 2024 to ₫12.3 trillion in Q3 FY 2024, ₫16.3 trillion in Q1 FY 2025 and now ₫18.1 trillion in Q3 FY 2025, while...
NYSE:WBI
NYSE:WBIEnergy Services

WaterBridge Infrastructure (WBI) Quarterly Loss Despite US$123.25m Revenue Tests Bullish Re Rating Hopes

Latest FY 2025 Earnings Snapshot WaterBridge Infrastructure (WBI) just posted its FY 2025 numbers with third quarter revenue of US$123.25 million and a basic EPS loss of US$0.02, while net income excluding extra items was a loss of US$0.67 million. The company has seen revenue move from US$89.80 million in the third quarter of 2024 to US$123.25 million in the same period of 2025. The trailing twelve month revenue figure in the dataset stands at US$733.30 million with a net loss of US$91.25...
NYSE:CXW
NYSE:CXWCommercial Services

Does Reactivating Leavenworth Facility Reshape CoreCivic’s Utilization Story And Investment Case (CXW)?

CoreCivic recently obtained a Special Use Permit for its Midwest Regional Reception Center in Leavenworth, Kansas, allowing the previously idled facility to resume operations and begin accepting detainees on a phased basis. This regulatory approval effectively brings an additional revenue-generating asset back online, with phased intake potentially enhancing utilization and supporting CoreCivic’s broader detention services footprint. We’ll now examine how reactivating the Midwest Regional...
NasdaqGM:TRUP
NasdaqGM:TRUPInsurance

Assessing Trupanion (TRUP) Valuation After New HABRI Partnership On Service Dog Research

Trupanion (TRUP) shares are in focus after the Human Animal Bond Research Institute announced a new partnership with the pet insurer, centering on research and support for service dogs and the broader human animal bond. See our latest analysis for Trupanion. Despite the HABRI partnership highlighting Trupanion's role in supporting the human animal bond, the stock has faced selling pressure, with a 90 day share price return of 32.03% decline and a 1 year total shareholder return of 31.47%...
NasdaqGS:CASH
NasdaqGS:CASHBanks

A Look At Pathward Financial (CASH) Valuation After Fresh Overweight And Outperform Analyst Calls

Piper Sandler’s decision to initiate coverage on Pathward Financial (CASH) with an Overweight rating, along with an average brokerage view of Outperform, has drawn fresh attention to the bank’s shares and recent return profile. See our latest analysis for Pathward Financial. The Piper Sandler initiation lands after a strong run, with Pathward Financial’s share price return of 22.82% over 90 days and year to date share price return of 26.85% feeding into a 1 year total shareholder return of...